Literature DB >> 26790365

HCV in 2015: Advances in hepatitis C research and treatment.

Barbara Rehermann1.   

Abstract

In 2015, new treatment regimens were revealed that achieve >95% cure rates for all HCV genotypes. The HCV polymerase structure was solved in catalytically relevant HCV replication steps and in the context of nucleotide analogue inhibition. Moreover, HCV research taught us new links between innate antiviral responses, lipid metabolism and intracellular membrane formation.

Entities:  

Mesh:

Year:  2016        PMID: 26790365     DOI: 10.1038/nrgastro.2015.227

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  11 in total

Review 1.  Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy.

Authors:  L B Dustin; B Bartolini; M R Capobianchi; M Pistello
Journal:  Clin Microbiol Infect       Date:  2016-08-31       Impact factor: 8.067

2.  Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.

Authors:  Hawwa Alao; Maggie Cam; Chithra Keembiyehetty; Fang Zhang; Elisavet Serti; Daniel Suarez; Heiyoung Park; Nicolaas H Fourie; Elizabeth C Wright; Wendy A Henderson; Qisheng Li; T Jake Liang; Barbara Rehermann; Marc G Ghany
Journal:  Hepatology       Date:  2018-07-16       Impact factor: 17.425

3.  Discovery of 2'-α-C-Methyl-2'-β-C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus.

Authors:  Debin Zeng; Rui Zhang; Quandeng Nie; Lin Cao; Luqing Shang; Zheng Yin
Journal:  ACS Med Chem Lett       Date:  2016-10-19       Impact factor: 4.345

Review 4.  Current progress in host innate and adaptive immunity against hepatitis C virus infection.

Authors:  Jijing Shi; Yuanyuan Li; Wenxian Chang; Xuexiu Zhang; Fu-Sheng Wang
Journal:  Hepatol Int       Date:  2017-06-22       Impact factor: 6.047

5.  Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs.

Authors:  Dustin B Stephens; April M Young; Jennifer R Havens
Journal:  Int J Drug Policy       Date:  2017-06-23

6.  Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin.

Authors:  Cody Orr; Johannes Aartun; Henry Masur; Shyam Kottilil; Eric G Meissner
Journal:  J Viral Hepat       Date:  2018-12-03       Impact factor: 3.728

7.  Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons.

Authors:  Stephen M Laidlaw; Svetlana Marukian; Rachel H Gilmore; Siobhán B Cashman; Volodymyr Nechyporuk-Zloy; Charles M Rice; Lynn B Dustin
Journal:  Gastroenterology       Date:  2017-04-26       Impact factor: 22.682

Review 8.  Hepatitis C virus infection in children and adolescents.

Authors:  James E Squires; William F Balistreri
Journal:  Hepatol Commun       Date:  2017-03-23

9.  Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture.

Authors:  Yucel Aydin; Milad Chedid; Srinivas Chava; Donkita Danielle Williams; Shuanghu Liu; Curt H Hagedorn; Suchitra Sumitran-Holgersson; Krzysztof Reiss; Krzysztof Moroz; Hua Lu; Luis A Balart; Srikanta Dash
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

10.  Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection.

Authors:  Eric G Meissner; Anita Kohli; Jeanette Higgins; Yu-Jin Lee; Olga Prokunina; David Wu; Cody Orr; Henry Masur; Shyam Kottilil
Journal:  Hepatol Commun       Date:  2017-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.